The use of pegylated interferon a‐2a in a cohort of Greek patients with mycosis fungoides

Patsatsi, Aikaterini; Papadavid, E.; Kyriakou, Aikaterini; Georgiou, Elisavet; Κoletsa, Triantafyllia; Avgeros, Chrysostomos; Koumourtzis, Marios; Tsamaldoupis, Athanasios; Lazaridou, E.; Stratigos, Alexandros; Nikolaou, Vassiliki

doi:10.1111/jdv.17795

Cited by 11 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found a lower rate of complete remission (12% vs 36%), but a higher rate of partial response (40% vs 36%) than in the current study, possibly due to the lower case numbers in the current study ( 12 ). In comparison with Patsatsi et al’s study PEG-IFNα was only combined with skin-directed therapy in the current study, explaining the high response rates ( 13 ). They reported a 75% ORR for stage IB and 55% for all stages, underscoring that PEG-IFNα will belong to standard of care in the treatment of cutaneous T-cell lymphoma.…”

Section: Discussioncontrasting

confidence: 69%

Use of Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma: A Retrospective Case Collection

Gosmann,

Stadler,

Quint

et al. 2023

Acta Derm Venereol

View full text Add to dashboard Cite

Mycosis fungoides and Sézary syndrome are rare and largely incurable types of cutaneous T-cell lymphoma with limited therapeutic options. In 1984 Bunn et al. reported that interferon alpha is an efficient monotherapy in cutaneous T-cell lymphoma and 14 years later it was shown in a prospective, randomized trial that a combination of interferon alpha and psoralen plus ultraviolet A therapy (PUVA) is most efficient in the treatment of cutaneous T-cell lymphoma. Since then interferon alpha as single agent or, most often, in combination with phototherapy and/or retinoids has been integrated as standard of care in cutaneous T-cell lymphoma guidelines worldwide. However, production of interferon alpha was discontinued recently worldwide and pegylated interferon alpha-2a (PEG-IFNα) has been used as an alternative therapy. In contrast to numerous interferon alpha studies, only a few studies focusing on PEG-IFNα are available. Therefore, the aim of this study was to conduct a retrospective data collection to report on the efficacy, adverse events and therapy regimens of PEG-IFNα in cutaneous T-cell lymphoma. In 28 patients with cutaneous T-cell lymphoma treated in Germany and in the Netherlands, 36% of patients achieved complete remission, 36% partial remission and 29% stable disease. Eighteen percent of patients developed adverse events during therapy, which led to the discontinuation of PEG-IFNα therapy in 2 patients. The most common concomittant therapies were oral PUVA phototherapy and local radiotherapy. In conclusion, PEG-IFNα, especially in combination with skin-directed therapies, is an effective treatment option for cutaneous T-cell lymphoma in clinical practice.

show abstract

Section: Discussioncontrasting

confidence: 69%

Use of Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma: A Retrospective Case Collection

Gosmann,

Stadler,

Quint

et al. 2023

Acta Derm Venereol

View full text Add to dashboard Cite

show abstract

“…Additionally, a proposed management algorithm is presented. Tere are few publications assessing treatment outcomes with pegylated interferon in the forms of case reports and clinical trials [24][25][26][27][28][29][30][31][32]; therefore, a review of the literature assessing the efcacy of PEG-IFN for treatment of CTCL will be presented and discussed.…”

Section: Introductionmentioning

confidence: 99%

Transitioning to Pegylated Interferon for the Treatment of Cutaneous T‐Cell Lymphoma: Meeting the Challenge of Therapy Discontinuation and a Proposed Algorithm

Osman

Chia

Street

et al. 2023

Dermatologic Therapy

View full text Add to dashboard Cite

Cutaneous T-cell lymphoma (CTCL) is an uncommon non-Hodgkin lymphoma characterized by skin involvement, with the most recognized subtypes being mycosis fungoides (MF) and Sezary syndrome (SS). Interferon has been an established treatment for MF/SS since 1984 and is integrated into management guidelines internationally. In 2019, manufacturers abruptly discontinued interferon-α2b and interferon-α2a. Many alternative systemic therapies in MF/SS remain unfunded or unavailable in Canada, presenting a unique challenge. Although off-label use of pegylated interferon is a logical substitute, there are no established dosing guidelines and limited published experience. This case series provides a single-center experience on pegylated interferon-α2b for treatment of MF/SS, a suggested management algorithm, and a review of the literature. All patients identified in the Calgary Cutaneous Lymphoma Program with stage IIB–IVB MF/SS treated with interferon-α2b (4.5–9 MU/week) were switched to once weekly pegylated interferon (90 μg, 0.5 mL) between February and July 2021. Response was monitored using the mSWAT and SkinDex-29 tools. Eight patients were switched to pegylated interferon, with a median disease duration of 69 months (range: 8–275 months). Five out of eight patients remain on pegylated interferon, with the remainder having switched to preplanned therapies. Two patients required dose reduction due to side effects, including grade II anemia and mood changes. The remaining patients had normal laboratory investigations and no additional side effects. Uncommon lymphomas like MF/SS have limited treatment options, and the impact of abrupt product discontinuation is substantial. We propose a management algorithm for the transition of patients from interferon to pegylated interferon.

show abstract

Section: Introductionmentioning

confidence: 99%

Transitioning to pegylated interferon for the treatment of cutaneous T-cell lymphoma: meeting the challenge of therapy discontinuation and a proposed algorithm

Osman¹,

Hardin²,

Street³

et al. 2022

European Journal of Cancer

View full text Add to dashboard Cite

The use of pegylated interferon a‐2a in a cohort of Greek patients with mycosis fungoides

Cited by 11 publications

References 4 publications

Use of Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma: A Retrospective Case Collection

Use of Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma: A Retrospective Case Collection

Transitioning to Pegylated Interferon for the Treatment of Cutaneous T‐Cell Lymphoma: Meeting the Challenge of Therapy Discontinuation and a Proposed Algorithm

Transitioning to pegylated interferon for the treatment of cutaneous T-cell lymphoma: meeting the challenge of therapy discontinuation and a proposed algorithm

Contact Info

Product

Resources

About